A n increasing number of patients are receiving a direct oral anticoagulant (DOAC) (ie, dabigatran, rivaroxaban, apixaban, or edoxaban) for stroke prevention in atrial fibrillation and for the treatment of venous thromboembolism. Annually, approximately 10% of such patients will require DOAC interruption for an elective procedure, 1 and many of these patients will require a neuraxial procedure for anesthesia or pain control. In response to the increasing need for managing DOACs in a perioperative setting, several reviews provide clinical guidance regarding the perioperative management of patients on DOACs.
n increasing number of patients are receiving a direct oral anticoagulant (DOAC) (ie, dabigatran, rivaroxaban, apixaban, or edoxaban) for stroke prevention in atrial fibrillation and for the treatment of venous thromboembolism. Annually, approximately 10% of such patients will require DOAC interruption for an elective procedure, 1 and many of these patients will require a neuraxial procedure for anesthesia or pain control. In response to the increasing need for managing DOACs in a perioperative setting, several reviews provide clinical guidance regarding the perioperative management of patients on DOACs. [2] [3] [4] More recently, the American Society of Regional Anesthesia (ASRA), in collaboration with other pain medicine societies, issued practice guidelines for the management of DOAC-treated patients who require anticoagulant interruption for interventional spine and pain procedures. 5 These guidelines recommend that the preprocedure interruption interval for the DOACs should be 4 to 6 days for dabigatran, 3 days for rivaroxaban, and 3 to 5 days for apixaban. The interruption intervals allow a period of at least 5 elimination half-lives (but often longer) to elapse between the last DOAC dose and the procedure, corresponding to a residual anticoagulant effect of~3% (~6% if 4 drug half-lives elapsed). These guidelines also recommend that DOACs are resumed 24 hours after the procedure. It is noteworthy that the guideline authors state that a grading for these recommendations, whether strong or weak, cannot be given because of the lack of evidence.
Against this background, the purpose of this communication is 3-fold: (1) to express concern that the 2015 ASRA recommendations pertaining to the periprocedural management of DOACs have been developed prematurely, without the requisite evidence; (2) to share emerging data regarding the effect of DOAC interruption on the residual anticoagulant effect at the time of a procedure that will help inform this discussion; and (3) to sound a call to action for more research in this clinical domain to inform best practices.
DISCUSSION
Regarding our initial point, we believe a distinction should be made between practice guidelines and clinical guidance. 6 Whereas practice guidelines are anchored, typically, on evidence from well-designed clinical studies, clinical guidance is considered expert opinion that is useful when high-quality evidence is not yet available (eg, early development of new treatment) or unlikely to be obtained (eg, rare disease management). This distinction is important because clinicians, institutions, and policymakers typically view practice guidelines as what "should (or should not) be done," and nonadherence to such guidelines may affect perceived quality of practice and may have medicolegal implications. On the other hand, a clinical guidance document suggests management but falls short of informing clinicians what "should (or should not) be done." Regarding the periprocedural management of DOACs, clinical evidence is lacking, as the ASRA guidelines point out, yet definitive practice recommendations are provided regarding the periprocedural interruption and resumption of DOACs. Although the authors qualify these recommendations by stating that a grade/strength cannot be assigned because of this lack of evidence, one cannot have it both ways: one must choose whether to develop practice guidelines, with associated evidence-based, graded recommendations, or a clinical guidance that suggests management but refrains from making recommendations per se. The former can have far-reaching clinical implications, whereas the later allows flexibility in clinical practice and acknowledges implicitly the lack of high-quality evidence. We are concerned that the recommendations provided by ASRA, although well intentioned, may be counterproductive and may increase patient risk by establishing unsubstantiated protocols for periprocedural DOAC management. This, in turn, may hinder research that aims to define best practices in this clinical domain.
In general terms, the management goal in DOAC-treated patients, who are having a procedure associated with a high bleed risk (any neuraxial procedure), is to ensure minimal to no anticoagulant effect at the time of the procedure and at the same time minimize the period without protection against thromboembolism. Periprocedural management should be associated with a low risk of bleeding of 1% to 2%, 7 but it is acknowledged that for some procedures a 1% to 2% rate may be too high because the "closed" location of such bleeds (epidural, intracerebral, pericardial) can have devastating consequences. Consequently, to ensure minimal to no residual anticoagulant effect in such high-risk patient groups, we agree with the ASRA that the elimination half-lives of an anticoagulant should guide the "when to stop" decision. We also applaud the efforts of the ASRA to provide a comprehensive review of the key pharmacologic properties of antithrombotic drugs. Where we appear to differ with the ASRA guidelines is that the recommended DOAC interruption intervals should be based not only the DOAC halflife but also, more importantly, on the interruption interval that leads to a measured minimal to no residual anticoagulant effect prior to a high-bleed-risk procedure. Indeed, the measured residual anticoagulant effect has been used to determine interruption intervals for older anticoagulants and also should be applied to the newer DOACs.
We recently assessed in dabigatran-treated patients the effect of a standardized preprocedure interruption protocol (≥24-hour interruption if low bleed risk, ≥48-hour interruption if high bleed risk) on residual anticoagulant effect at the time of a procedure. 8 This residual anticoagulant effect was measured by the activated partial thromboplastin time (aPTT), the thrombin time (TT), and the dilute TT (dTT). The dTT is considered the most reliable test to measure the anticoagulant effect of dabigatran; the aPTT is also reliable when a high sensitivity assay is used, whereas the TT is a poorly calibrated and overly sensitive test. 9 In this study, 80% to 86% of patients had no detectable anticoagulant effect at the time of the procedure, but it was concluded that a longer interruption interval would be required for high-bleed-risk procedures, such as neuraxial procedures, so that a higher proportion of patients (eg, >95%) would have no detectable residual anticoagulant effect.
Herein, we present (previously unpublished) findings among those patients in whom there is a longer dabigatran interruption interval of at least 36 hours for low-bleed-risk procedures (last dose 2 days preprocedure) and at least 60 hours for high-bleed-risk procedures (last dose 3 days preprocedure). For example, in patients undergoing a high-bleed-risk procedure with a creatinine clearance greater than 50 mL/min, in whom the half-life of dabigatran is 12 to 15 hours, 10 their last dose would be 3 days preprocedure (4 doses skipped plus none on procedure day). Assuming dabigatran is taken at 6 PM (usually taken with meals) and the procedure is between 8 AM and 2 PM 3 days later, this corresponds to an interruption interval of 62 to 68 hours, or 4 to 5 half-lives (ie, 12-hour half-life Â 5 half-lives = 60 hours; 15-hour half-life Â 5 halflives = 75 hours). In patients with a creatinine clearance of 30 to 50 mL/min, a longer interruption interval is required (last dose 5 days preprocedure), whereas in patients having a low-bleedrisk procedure a shorter interval is used. In this subgroup analysis, among patients who stopped dabigatran according to the previously mentioned interruption schedule, the residual anticoagulant effect is shown in Table 1 . Thus, in high-bleed-risk patients, 22 (100%) of 22 patients had a normal aPTT, and 21 (95.5%) of 22 patients had a normal dTT at the time of surgery. The dTT in the 1 patient with an elevated dTT was only slightly increased at 31 ng/mL.
Regarding our third point, although our proposed DOAC therapy interruption protocol for dabigatran-treated patients appears to yield a minimal or no residual anticoagulant effect prior to a high-bleed-risk procedure, such preliminary results require confirmation in larger, well-designed studies. Indeed, because of the increasing use of DOACs, the need for research to inform periprocedural management practices is timely and urgently needed because of the implications of interrupting DOAC too early (increased thrombosis risk) and interrupting too late (increased bleed risk). The ongoing PAUSE trial (clinicaltrials.gov NCT02228798) is one such study that plans to assess the residual anticoagulant effect with this protocol in 1100 patients taking each DOAC and who have an elective surgery/ procedure, of whom one-third will undergo a high-bleed-risk surgery/procedure and will be subjected to the previously mentioned protocol for dabigatran interruption. Separate interruption protocols are used for patients on rivaroxaban or apixaban. However, additional research is needed in this area, especially from anesthesiology research groups. Our mutual aim should be toward an evidence-based approach to the perioperative management of patients on DOACs who require neuraxial procedures. Ultimately, it is evidence that should drive practice (and guideline recommendations), not practice driving evidence. *Three-day interruption interval (4 doses skipped) for high-bleed-risk procedure and 2-day interruption interval (2 doses skipped) for low-bleed-risk procedure.
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